# Adebrelimab and Chidamide for Pancreatic Cancer

> **NCT06584227** · PHASE2 · RECRUITING · sponsor: **Liu Xiufeng** · enrollment: 45 (estimated)

## Conditions studied

- Pancreatic Cancer, Adult

## Interventions

- **DRUG:** Adebrelimab and Chidamide Combined with Gemcitabine and S1

## Key facts

- **NCT ID:** NCT06584227
- **Lead sponsor:** Liu Xiufeng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2026-07-10
- **Final completion:** 2027-05-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06584227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06584227, "Adebrelimab and Chidamide for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06584227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*